Is the vitamin D status of patients with COVID-19 associated with reduced mortality?

Paulo R Bignardi, PhD[a], Paula de Andrade Castello[a], Bruno de Matos Aquino[a], Vinicius Daher Alvares Delfino, MD, PhD[a,b]

Affiliations:

[a]School of Medicine, Pontifícia Universidade Católica do Paraná, Londrina, Brazil

[b] Universidade Estadual de Londrina, Londrina, Brazil

* Correspondence author: Prof. Paulo R. Bignardi. e-mail: pbignardi@gmail.com, School of Medicine. Address: 485 Jockey Club ave – Hípica – Londrina – Paraná – Brazil, Zip code 86072-360. Phone: +5504333726042.

:

ABSTRACT

Objective. A systematic review with meta-analysis was performed to assess a possible association between plasma vitamin D levels and mortality in patients with COVID- 19. **Methods**. PubMed, EMBASE, and Cochrane Library databases were searched. Studies involving COVID-19 patients that reported an association between plasma vitamin D levels and COVID-19 mortality published until February 5, 2021, were included. The risk ratio (RR) and confidence interval (CI) were pooled using a fixed-effects or random-effects model. **Results**. A total of 11 studies that measured plasma vitamin D levels at admission were included in the meta-analysis, ten cohorts and one case-controls. Low plasma vitamin D levels (25(OH)D) in patients with COVID-19 were not associated with mortality (RR=1.35, 95%CI 0.84–1.86). Subgroup analysis by vitamin D cut-off (<20 or 25 ng/ml and <10 or 12 ng/ml) showed were not associated with mortality. When the RR in mortality analysis was calculated included four studies that did not perform adjusted analysis for confounding factors, the result was 1.43 (95% CI 1.18-1.69), suggesting that confounders may have led many observational studies to incorrectly estimate the association between vitamin D status and mortality in COVID-19 patients. **Conclusion**. Deficient vitamin D levels were not associated with a higher mortality rate in patients with COVID-19. Randomized clinical trials are needed to assess this association.

Keywords: 1,25-dihydroxyvitamin D; 25-hydroxyvitamin D; Meta-analysis; Systematic Review, SARS-Cov2.

INTRODUCTION

Since the first case registered in December 2019 in the city of Wuhan, Hubei Province, China, COVID-19 has spread rapidly throughout the world for presenting strong contagious and infectious characteristics [1–3], which have caused 2,309,370 deaths until February 8th, 2020, in 198 countries[4].

Worldwide data from the pandemic demonstrate a mortality rate of 0.9% in patients without comorbidities, which increases progressively based on the number of comorbidities and the patients' age[5]. Studies relating vitamin D levels to Acute respiratory infections[6] led to the carrying out an ecological study that showed that countries where the plasma mean vitamin D in the population are low, had higher infection rates and mortality SARS-CoV2[7].

Isaia et al.[8] found a correlation between regions with higher levels of solar ultraviolet (UV) radiation and lower rates of morbidity and mortality related to COVID-19. The hypothesis discussed by the authors is that it may be related to vitamin D levels. Exposure to UV radiation determines the photo-conversion of the 7-dehydrocholesterol in the skin to pre-vitamin D3[9]. There are two forms of vitamin D (D2 and D3), and the primary source of vitamin D3 (about 80% of the vitamin D organic stores) is via UV[10]. Vitamin D from the skin and diet is metabolized in the liver to 25-hydroxyvitamin D (25(OH)D), the form used to determine patients' vitamin D status, is hydroxylated in the kidneys in the active form 1,25 dihydroxyvitamin D (1,25$(OH)_2$D).

Vitamin D insufficiency is defined as a blood level of 25(OH)D <30 ng/mL, vitamin D deficiency is a blood level of 25(OH)D <20 ng/mL, and severe vitamin D deficiency as a blood level of 25(OH)D < 10 ng/ml [11, 12] or <12 ng/ml, according to some authors[13, 14]. Small observational studies relating vitamin D deficiency or

insufficiency to COVID-19 outcomes have emerged with divergent results[15–19]. Thus, we conducted a systematic review followed by meta-analysis to assess a possible association between plasma vitamin D levels and mortality in patients with COVID- 19.

METHODS

Data Search

Two investigators searched MEDLINE, EMBASE, and Cochrane Library. Studies published until February 5, 2021, were included. The following search strategy was used: (coronavirus OR "coronavirus infections" OR COVID-19 OR "severe acute respiratory syndrome coronavirus 2") AND ("vitamin D). The language of the searches was limited to English, Spanish, and Portuguese.

Study selection

Two independent authors screened the studies. Disagreements were resolved through discussion among all authors. Summaries of retrieved articles were reviewed to exclude irrelevant studies, followed by reading full text for screening.

Studies were included if they met the following inclusion criteria: (1) Hospitalized patients with COVID-19. All studies used throat swab SARS-CoV-2 real-time reverse transcription-polymerase chain reaction (RT-PCR) nucleic acid to confirm COVID-19 diagnosis; (2) COVID-19 patients with deficient or insufficient vitamin D status and plasma vitamin D (25(OH)D) levels measured on hospital admission (up to 48 hours after

diagnosis); (3) COVID-19 patients with sufficient vitamin D status as the comparator; (4) examined the association between vitamin D status and mortality. Ecological, case reports, cross-sectional, animal model study, and studies that did not mention that plasma vitamin D levels were measured at admission were excluded.

Data Extraction

Eligible studies included assessing death or disease severity in individuals with plasma vitamin D. They should provide the odds ratio (OR), risk ratio (RR), or hazard ratio (HR) with 95% confidence intervals (CI). Inclusion was not restricted by study size.

Data extracted included authors, study design, country of origin, demographic characteristics (age and sample size), COVID-19 diagnosis, outcomes relevant studies on the study question. Two independent investigators performed data extraction. Disagreements were resolved through discussion among all authors.

Results evaluation

The analysis focused on the mortality outcome in patients with COVID-19 within the low plasma vitamin D levels group compared with the sufficient plasma vitamin D level group. We performed one stratified analysis by cut-off vitamin D (<20 or 25 ng/ml and <10 or 12 ng/ml), and a second stratified analysis using studies that provided analysis adjusted for confounding factors and studies that did not. For the present meta-analysis, vitamin D levels were standardized to ng/ml; studies that provided vitamin D levels in nmol/l had these levels transformed into ng/ml[10]. Besides, a sensitivity analysis was performed, omitting each study to detect the influence on the overall effect's estimate.

Quality assessment and statistical analysis

This systematic review was conducted following the Preferred Items guidelines for Reporting for Systematic Reviews and Meta-Analysis (PRISMA), and this study has not been registered.

The New-Castle-Ottawa quality scale[20] was used to evaluate the quality of the observational studies. Studies included in the meta-analysis reported OR, HR, or RR. For studies that did not report these effects, the RR calculation was based on the Cochrane Handbook for Systematic Reviews [21].

Effect estimates with the most significant degree of adjustment for potential confounding factors were extracted. HR was considered comparable to RR. For studies that reported OR, a corrected RR was computed as already described[22]. Pooled RR and 95% confidence interval (CI) were calculated using a fixed or random-effects model according to the studies homogeneity. The Cochran Q test and the I^2 statistic were used to evaluate the statistical significance and degree of heterogeneity between the studies, respectively. The statistic $I^2 \geq 50\%$ reveals substantial heterogeneity. Finally, the publication bias was examined by the Egger test and a funnel plot. All analyses were performed with Stata/SE v.14.1 software (StataCorpLP, USA).

RESULTS

Characteristics of the selected studies

Seven-hundred and seventy-two (772) studies were identified through database research. Of these, 653 studies were duplicate articles or were excluded based on predetermined eligibility criteria during title/abstract review. According to the inclusion and exclusion criteria, we identified 11 studies[23, 24, 33, 25–32] that were eligible for this review and meta-analysis (Fig. 1), involving 1,347 participants. Ten were cohort[23, 24, 26–28, 30–33], and one case-control[25]. The characteristics of selected studies and participants are summarised in Table 1.

Plasma vitamin D level and mortality in patients with COVID-19

The mortality outcome was extracted from the 11 studies. Bennouar et al.[29] and Radujkovic et al.[26] were included twice because they analysed two cut-offs of vitamin D, <10 ng/ml and <20 ng/ml. Figure 2 shows that the mortality in patients with deficient plasma vitamin D levels did not differ from patients with sufficient plasma vitamin D levels (RR=1.35, 95%CI 0.84–1.86, I^2=62.3%). Analysis by vitamin D level (Fig. 2) showed a RR=1.34 (95% CI 0.79-1.89, I2 = 69.6%) for studies with plasma vitamin D <20 or 25 ng/ml, and RR=1.50 (95% CI 0.02-3.02, I^2 = 2.4%) for studies with plasma vitamin D <10 or 12 ng/ml.

Subgroup analysis (Fig. 3), including studies that performed adjustments for age and at least one more confounding factor (obesity, hypertension, diabetes, chronic kidney disease, and cardiovascular disease), revealed an RR=1.49 (95% CI 0.44-2.55, I^2 =

60.1%). The analysis, including studies that did not mention adjustment for confounders, showed an increased mortality risk (RR=1.43, 95%CI 1.18-1.69, I^2=2.2%).

Sensitivity analyses, assessment of heterogeneity and risk of bias

Table 2 shows sensitivity analyses performed, excluding one study that adjusted confounding factors at a time for the mortality outcome. There was no change in Cochran`s Q test, and the I^2 varied from 24.1% to 65.0%, persisting the same results in all scenarios.

The risk of bias in studies is detailed in Table 3. The estimated bias coefficient was 0.103, with *P*-value >0.05, indicating no small-study effects. A funnel plot was performed but failed to detect possible small study effects (Fig. 4). Therefore, the tests provide weak evidence for the presence of publication bias.

DISCUSSION

This is the first systematic review with meta-analysis to assess only studies that measured plasma vitamin D levels in patients close to the diagnosis of COVID-19. Observational studies have associated low plasma vitamin D levels and poor outcomes in patients with COVID-19. However, many of these studies used the plasma vitamin D level measured from a few months to years before the diagnosis of COVID-19[34, 35]. The biological variability of vitamin D is known, and its plasma levels can vary from 13 to 26% in 4 months. Plasma vitamin D can also vary with age and the appearance of comorbidities[36–40].

This study did not show an association between vitamin D status in COVID-19 patients and increased mortality risk. The overall analysis of mortality did not reveal an association between low plasma vitamin D levels and mortality. Likewise, the subgroup analysis with the studies that perform adjusted analysis with age and at least one more confounder did not show this association.

However, an analysis including only studies that did not performed adjusted analysis with confounders revealed an association between low plasma vitamin D levels and an increased risk of death (1.43-fold), which shows that confounding factors may have driven many previous studies results. Therefore, our meta-analysis suggests that vitamin D status does not have a causal effect on mortality in COVID-19 patients.

Patchen et al. aiming to investigate the causality of the association between serum vitamin D status and severity of COVID-19 infection, studied single nucleotide polymorphisms (SNPs) related to the risk of vitamin D deficiency. They found no association between genetically predicted differences in long-term vitamin D nutritional status and poor outcomes in patients with COVID-19[41].

Hypovitaminosis D shares many risk factors with the severe form of COVID-19. Older age, obesity, chronic kidney disease, diabetes, hypertension, and cardiovascular disease are some critical risk factors that have been reported as associated with the severity of COVID-19[42–45]. There is evidence that vitamin D deficiency can be caused by older age, obesity, and chronic kidney disease[46–51]. Type 2 diabetes, hypertension, and cardiovascular disease also are associated with vitamin D deficiency [52, 53].

It is known that vitamin D has a role in modulating the immune response, and its deficiency is associated with an increased risk of developing viral and bacterial infections [54, 55]. However, it may be that its role in preventing the mortality of patients with COVID-19 is outweighed by other mechanisms involved in the pathophysiology of the disease.

The liver hydroxylates vitamin D to 25(OH)D (Calcifediol), a form found in the blood with a 3-week plasma half-life (whole-body half-life is of 2–3 months)[56]. Plasma levels of Calcifediol are generally used to check people`s vitamin D status. Calcifediol is hydroxylated to its active form 1,25$(OH)_2$D, which has a plasma half-life of 4 hours, mainly in the kidneys but also in some other extra-renal sites, including pulmonary epithelial cells[10, 56]. Plasma level of 1,25$(OH)_2$D is roughly 1000-fold lower compared with Calcifediol[57].

The kidney is the main organ for the regulation of serum 1,25 $(OH)_2$D[58]. It is known that the ACE2 protein, present in renal and lung cells, is a target for SARS-CoV2 to enter these cells[59, 60]. Renal dysfunction caused directly by the virus or indirectly by the presence of acute kidney associated with COVID-19 infection may lead to a reduction in the activity of 1-alpha hydroxylase, the enzyme that converts Calcifediol to 1,25$(OH)_2$D[61, 62].

Therefore, a possible hypothesis that could explain our findings would be that tissue damage in the kidneys and to a lesser extent in the lung caused by SARS-CoV2 may lead to an active decrease of 1,25(OH)D, responsible for the majority of biological actions of Vitamin D, but not in the form usually determined in plasma, Calcifediol. Previous studies showed that blood 25(OH)D levels may not correlate with blood 1,25(OH)2D levels in some clinical conditions [63–65].

Reduced calcium and phosphorus were found in critically ill COVID-19 patients, which may indicate a reduction of 1,25$(OH)_2$D in these patients since the active form of vitamin D is an essential regulator of calcium and phosphorus levels acting in intestinal absorption and renal reabsorption[58].

Despite the well-known autocrine and paracrine production of 1,25$(OH)_2$D cells in the immune system, it is difficult to predict whether plasma levels do not influence the immune response against SARS-CoV2. Furthermore, Playford et al. findings that plasma levels of 1,25$(OH)_2$D, but not 25(OH)D were associated with cardiovascular risk factors, a common outcome in patients with severe COVID-19[66]. Likewise, Nguyen et al. findings that plasma levels of 1,25(OH)2D were a better predictor of mortality by sepsis than Calcifediol[67]. In addition, 1,25$(OH)_2$D antiviral action against SARS-CoV2 and other virus has been proposed[68, 69].

This study has several strengths. To our knowledge, this is the first meta-analysis associating plasma vitamin D levels measured on or near hospital admission of patients with COVID-19, and that included studies that performed analysis adjusted with confounders. The main study limitations were analysis that has used different cut-offs of plasma vitamin D, substantial heterogeneity, and observational design of the selected studies.

CONCLUSION

These results suggest that plasma vitamin D status is not associated with mortality in COVID-19 patients and that confounders may have led to the detrimental effects of low plasma 25(OH)D levels on COVID-19 patients observed in some previous studies. Large randomized clinical trials are needed to assess the effects of vitamin D levels, including 1,25$(OH)_2$D, on mortality of hospitalized patients with COVID-19.

REFERENCES

1. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med. 2020;2020:1–3. doi:10.1093/jtm/taaa008.

2. Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;:92.

3. WHO. WHO | Pneumonia of unknown cause – China. WHO. 2020. http://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 16 Aug 2020.

4. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. WHO. 2020. https://covid19.who.int/. Accessed 19 Dec 2020.

5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;:1.

6. Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, et al. Vitamin D supplementation to prevent acute respiratory infections: Individual participant data meta-analysis. Health Technol Assess (Rockv). 2019;23:1–44.

7. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020;32:1195–8. doi:10.1007/s40520-020-01570-8.

8. Isaia G, Diémoz H, Maluta F, Fountoulakis I, Ceccon D, di Sarra A, et al. Does solar ultraviolet radiation play a role in COVID-19 infection and deaths? An environmental ecological study in Italy. Sci Total Environ. 2020; xxxx:143757. doi:10.1016/j.scitotenv.2020.143757.

9. Norval M, Björn LO, De Gruijl FR. Is the action spectrum for the UV-induced production of previtamin D 3 in human skin correct? Photochemical and Photobiological Sciences. 2010;9:11–7. doi:10.1039/b9pp00012g.

10. Sahota O. Understanding vitamin D deficiency. Age and Ageing. 2014;43:589–91.

11. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805–6.

12. Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266–81.

13. Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. European Journal of Clinical Nutrition. 2020;74:1498–513. doi:10.1038/s41430-020-0558-y.

14. Cashman KD. Vitamin D Deficiency: Defining, Prevalence, Causes, and Strategies of Addressing. Calcified Tissue International. 2020;106:14–29. doi:10.1007/s00223-019-00559-4.

15. Brenner H, Holleczek B, Schoettker B. Vitamin D insufficiency and deficiency and mortality from respiratory diseases in a cohort of older adults: potential for limiting the death toll during and beyond the COVID-19 pandemic. 2020.

16. Kerget B, Kerget F, Kiziltunç A, Koçak AO, Araz Ö, Yilmazel Uçar E, et al. Evaluation of the relationship of serum vitamin d levels in covid-19 patients with clinical course and prognosis. Tuberk Toraks. 2020;68:227–35.

17. Ye K, Tang F, Liao X, Shaw BA, Deng M, Huang G, et al. Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study. J Am Coll Nutr. 2020;:1–8. doi:10.1080/07315724.2020.1826005.

18. Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory

failure due to COVID-19. J Endocrinol Invest. 2020. doi:10.1007/s40618-020-01370-x.
19. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr Clin Res Rev. 2020;14:561–5. doi:10.1016/j.dsx.2020.04.050.
20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5. doi:10.1007/s10654-010-9491-z.
21. Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect | Cochrane Training. Cochrane. 2019. https://training.cochrane.org/handbook/current/chapter-06. Accessed 9 Jun 2020.
22. Zhang J. What's the Relative Risk?: A Method of Correcting the Odds Ratio in Cohort Studies of Common Outcomes. JAMA J Am Med Assoc. 2008;280:1690–1.
23. Abrishami A, Dalili N, Mohammadi Torbati P, Asgari R, Arab-Ahmadi M, Behnam B, et al. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. Eur J Nutr. 2020. doi:10.1007/s00394-020-02411-0.
24. Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Van Den Abbeele K, et al. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J. 2020;2:1–6.
25. Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández-Hernández MA, López-Hoyos M, et al. Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection. J Clin Endocrinol Metab. 2020;XX Xx:1–11.
26. Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 2020;10:1–8. doi:10.1038/s41598-020-77093-z.

27. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients. 2020;12:1–13.

28. Smet D De, Smet K De, Herroelen P, Gryspeerdt S. Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality. Am J Clin Pathol. 2020;25:1–8.

29. Karahan S, Katkat F. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey. J Nutr Heal Aging. 2020;25 June.

30. Bennouar S, Cherif AB, Kessira A, Bennouar DE, Abdi S. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19. J Am Coll Nutr. 2020;0:1–11. doi:10.1080/07315724.2020.1856013.

31. Cereda E, Bogliolo L, Klersy C, Lobascio F, Masi S, Crotti S, et al. Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital. Clin Nutr. 2020; xxxx.

32. Vassiliou AG, Jahaj E, Pratikaki M, Keskinidou C, Detsika M, Grigoriou E, et al. Vitamin D deficiency correlates with a reduced number of natural killer cells in intensive care unit (ICU) and non-ICU patients with COVID-19 pneumonia. Hell J Cardiol. 2020.

33. Barassi A, Pezzilli R, Mondoni M, Rinaldo RF, DavÌ M, Cozzolino M, et al. Vitamin D in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with non-invasive ventilation support. Panminerva medica. 2021. doi:10.23736/S0031-0808.21.04277-4.

34. Hastie CE, Pell JP, Sattar N. Vitamin D and COVID-19 infection and mortality in UK Biobank. Eur J Nutr. 2020;:4–7. doi:10.1007/s00394-020-02372-4.

35. Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield MJ, et al. Greater risk of severe COVID-19 in black, asian and minority ethnic populations is

not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: Study of 1326 cases from the UK biobank. J Public Heal (United Kingdom). 2020;42:451–60.

36. Stamp TC, Round JM. Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature. 1974;24:563–5.

37. Levis S, Gomez A, Jimenez C, Veras L, Ma F, Lai S, et al. Vitamin D deficiency and seasonal variation in an adult south Florida population. J Clin Endocrinol Metab. 2005;90:1557–62.

38. Brescia V, Tampoia M, Cardinali R. Biological Variability of Serum 25-Hydroxyvitamin D and Other Biomarkers in Healthy Subjects. Lab Med. 2013;44:20–4.

39. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of Serum 25-Hydroxyvitamin D Levels During 14 Years in aPopulation-based Study and During 12 Months in an Intervention Study. Am J Epidemiol. 2010;171:903–8.

40. Fontanive TO, Dick NRM, Valente MCS, dos Santos Laranjeira V, Antunes MV, de Paula Corrêa M, et al. Seasonal variation of vitamin D among healthy adult men in a subtropical region. Rev Assoc Med Bras. 2020;66:1431–6. doi:10.1590/1806-9282.66.10.1431.

41. Patchen BK, Clark AG, Gaddis NM, Hancock DB, Cassano PA. Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study. medRxiv. 2021. http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250759.abstract.

42. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis. 2020;12:12493–503.

43. Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review). Mol

Med Rep. 2020;22:9–19.

44. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy Supplemental content. JAMA Intern Med. 2020;180:1345–55. doi:10.1001/jamainternmed.2020.3539.

45. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. 2020. doi:10.1016/j.ijid.2020.03.017.

46. Ghotane SG, Challacombe SJ, Gallagher JE. Fortitude and resilience in service of the population: a case study of dental professionals striving for health in Sierra Leone. BDJ Open. 2019;5:7. doi:10.1038/s41405-019-0011-2.

47. Pereira-Santos M, Costa PRF, Assis AMO, Santos CAST, Santos DB. Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes Rev. 2015;16:341–9.

48. Heaney RP, Horst RL, Cullen DM, Armas LAG. Vitamin D3 Distribution and status in the body. J Am Coll Nutr. 2009;28:252–6.

49. Walsh JS, Bowles S, Evans AL. Vitamin D in obesity. Curr Opin Endocrinol Diabetes Obes. 2017;24:389–94.

50. Gallagher JC. Vitamin D and Aging. Endocrinol Metab Clin North Am. 2013;42:319–32.

51. Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9. doi:10.3390/nu9040328.

52. Mitri J, Pittas AG. Vitamin D and diabetes. Endocrinology and Metabolism Clinics of North America. 2014;43:205–32. doi:10.1016/j.ecl.2013.09.010.

53. Skaaby T, Thuesen BH, Linneberg A. Vitamin D, cardiovascular disease and risk

factors. In: Advances in Experimental Medicine and Biology. Springer New York LLC; 2017. p. 221–30. doi:10.1007/978-3-319-56017-5_18.

54. Looman KIM, Jansen MAE, Voortman T, van den Heuvel D, Jaddoe VWV, Franco OH, et al. The role of vitamin D on circulating memory T cells in children: The Generation R study. Pediatr Allergy Immunol. 2017;28:579–87. doi:10.1111/pai.12754.

55. Wang T-T, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting Edge: 1,25-Dihydroxyvitamin D 3 Is a Direct Inducer of Antimicrobial Peptide Gene Expression . J Immunol. 2004;173:2909–12. doi:10.4049/jimmunol.173.5.2909.

56. Martinaityte I, Kamycheva E, Didriksen A, Jakobsen J, Jorde R. Vitamin D stored in fat tissue during a 5-year intervention affects serum 25-hydroxyvitamin d levels the following year. J Clin Endocrinol Metab. 2017;102:3731–8.

57. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Physiol. 2005;289:F8–28. doi:10.1152/ajprenal.00336.2004.

58. Yang C, Ma X, Wu J, Han J, Zheng Z, Duan H, et al. Low serum calcium and phosphorus and their clinical performance in detecting COVID-19 patients. J Med Virol. 2021;93:1639–51.

59. Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10:7448–64. doi:10.7150/thno.48076.

60. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertension Research. 2020;43:648–54. doi:10.1038/s41440-020-0455-8.

61. Huang CQ, Ma GZ, Tao MD, Ma XL, Liu QX, Feng J. The relationship among renal injury, changed activity of renal 1-α hydroxylase and bone loss in elderly rats with insulin resistance or Type 2 diabetes mellitus. J Endocrinol Invest. 2009;32:196–201.

doi:10.1007/BF03346452.

62. Werion A, Belkhir L, Perrot M, Schmit G, Aydin S, Chen Z, et al. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int. 2020;21:1–9. http://mpoc.org.my/malaysian-palm-oil-industry/.

63. Christensen MHE, Lien EA, Hustad S, Almås B. Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scand J Clin Lab Invest. 2010;70:281–6. doi:10.3109/00365511003797172.

64. Fleet JC, Replogle RA, Reyes-Fernandez P, Wang L, Zhang M, Clinkenbeard EL, et al. Gene-by-diet interactions affect serum 1,25-dihydroxyvitamin D levels in male BXD recombinant inbred mice. Endocrinology. 2016;157:470–81. doi:10.1210/en.2015-1786.

65. Li CH, Tang X, Wasnik S, Wang X, Zhang J, Xu Y, et al. Mechanistic study of the cause of decreased blood 1,25-Dihydroxyvitamin D in sepsis. BMC Infect Dis. 2019;19:1020. doi:10.1186/s12879-019-4529-7.

66. Playford MP, Dey AK, Zierold C, Joshi AA, Blocki F, Bonelli F, et al. Serum active 1,25(OH) 2 D, but not inactive 25(OH)D vitamin D levels are associated with cardiometabolic and cardiovascular disease in psoriasis. Atherosclerosis. 2019;289:44–50.

67. Nguyen HB, Eshete B, Lau KHW, Sai A, Villarin M, Baylink D. Serum 1,25-Dihydroxyvitamin D: An Outcome Prognosticator in Human Sepsis. PLoS Med. 2013;8. http://www.knowledge.scot.nhs.uk/sepsisvte.aspx.

68. Lee C. Controversial effects of vitamin d and related genes on viral infections, pathogenesis, and treatment outcomes. Nutrients. 2020;12:962. doi:10.3390/nu12040962.

69. Mok CK, Ng YL, Ahidjo BA, Hua Lee RC, Choy Loe MW, Liu J, et al. Calcitriol,

the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis. medRxiv. 2020.

Table 1. Characteristics of studies selected.

Author	Country	Study Design	Follow-up	Population	Age (years)	Outcomes	Sample Size	Exposure (n/cut-off)	Confounder adjusted
Abrishami et al[23]	Iran	Retrospective Cohort	February 28, 2020 to April 19, 2020	Hospitalized patients with COVID-19	55.18±14.98	Death and hospitalization	73	- Vitamin D ≤25ng/mL	Age, sex, and comorbidities
Baktash et al[24]	UK	Prospective cohort	1 March to 30 April 2020	Hospitalized patients aged ≥65 years with COVID-19	81 (65-102)*	Mortality secondary to COVID-19; NIV support and admission to HDU, COVID-19 radiographic changes on chest X-ray	70	39 (Vitamin D ≤12ng/mL)	Not adjusted
Barassi et al[33]	Italy	prospective Cohort	8 April to 25 May, 2020	Patients hospitalized with COVID-19	61 (24-92)*	Mortality	118	87 (Vitamin D ≤20ng/mL)	Not adjusted
Bennouar et al[30]	Algeria	Prospective cohort	July 6th to August 15th, 2020.	Severe COVID-19 Patients	62.3 ± 17.6	Mortality	120	32 (Vitamin D ≤12ng/mL) 35 (Vitamin D ≤20ng/mL)	Age, sex, acute kidney injury, cardiac injury, blood glucose, CRP, NLR, LDH, albumin and total cholesterol.
Cereda et al[31]	Italy	Cohort	March - April 2020	Hospitalized patients with COVID-19 i	77 (65-85)*	Mortality	129	99 (Vitamin D <20 ng/mL)	Age, CRP, and ischemic heart disease.
Hernández et al[25]	Spain	Case-control	March 10 to March 31, 2020	hospitalized patients aged ≥18 years with confirmed COVID-19	61 (47.5-70)*	COVID-19 severity (death and ICU admission)	216	vitamin D deficiency group: 162 (Vitamin D ≤ ≤20ng/mL)	Age, sex, BMI, smoking, diabetes mellitus, history of cardiovascular events, oral vitamin D supplements, CRP, and GFR

								vitamin D supplementation group: 19 (dose and type of drug no reported)	
Jain et al[26]	India	Prospective cohort	6 weeks	Patients with COVID-19 between 30 and 60 years	51.41 ± 9.12	Serum IL-6, serum TNF-α, serum ferritin, deaths and serum level of vitamin D	154	90 (Vitamin D <20 ng/mL)	Not adjusted
Karahan & Katkat[29]	Turkey	Retrospective cohort	April 1st, 2020 and May 20th, 2020	Adult patients with moderate and severe COVID-19	63.5 ± 15.3	Mortality	149	103 (Vitamin D <20 ng/mL)	Age, smoking, hyperlipidemia, diabetes mellitus, chronic kidney disease, chronic atrial fibrillation, congestive heart failure, acute kidney injury, eGFR, hemoglobin neutrophil count, lymphocyte count, white blood cell count, CRP, albumin, and calcium
Radujkovic et al[27]	Germany	Prospective cohort	18 March to 18 June, 2020	Inpatients and Outpatients diagnosed with COVID-19	60 (49–70)*	NVI and survival	93	29 (Vitamin D <12 ng/mL) 47 (Vitamin D <20ng/mL)	Age, gender, and presence of comorbidity
Smet et al[28]	Belgium	Retrospective cohort	March 1, 2020, to April 7, 2020	Hospitalized patients with COVID-19	69 (52-80)	COVID-19 severity (stage disease and death)	186	109 (Vitamin D <20 ng/mL)	Age, sex, coronary artery disease and diabetes.
Vassiliou et al[32]		Prospective cohort	18 March to 25 May, 2020	Hospitalized patients with COVID-19	61 ± 14	Mortality and NVI	39	32 (Vitamin D <20 ng/mL)	Not adjusted

25OHD: 25-hydroyvitamin D, ALT: alanine transaminase, AST: aspartate aminotransferase, BMI: body-mass index, CK: creatine kinase, CRP: C reactive protein, GFR: glomerular filtration rate, HDU: High dependency unit, IL-6: interleukin-6; ICU: Intensive Care Unit, LDH: lactate dehydrogenase, NLR: neutrophils to lymphocyte ratio, NVI: Non-invasive ventilation, PCT: procalcitonin, PTH: parathyroid hormone.
* Data represented as median (IQR). ** Data represented as mean (CI 95%)

Table 2. Sensitive analysis for the mortality outcome, including studies that performed adjusted analysis for confounders.

Study omitted	**RR**	**95% CI**	**I^2**	***P*-value***
Abrishami et al	1.45	0.38-2.53	63.7%	>0.05
Bennouar et al (<10 ng/ml)	1.49	0.39-2.50	62.9%	>0.05
Bennouar et al (<20 ng/ml)	1.44	0.34-2.54	63.7%	>0.05
Cereda et al	1.89	0.84-2.94	24.1%	>0.05
Hernández et al	2.05	0.45-3.65	65.0%	>0.05
Kaharan & Katkat	1.30	0.31-2.29	58.1%	>0.05
Radujkovic et al (<12 ng/ml)	1.46	0.41-2.50	62.7%	>0.05
Radujkovic et al (<20 ng/ml)	1.51	0.43-2.58	64.7%	>0.05
Smet et al	0.88	0.04-1.72	25.6%	>0.05

* value for heterogeneity among studies assessed with Cochran's Q test.

Table 3 Risk of bias from studies included in meta-analyzes. (Newcastle Ottawa scale)

CASE-CONTROL STUDIES	**SELECTION**				**COMPARABILITY**		**EXPOSURE**			**TOTAL OF STARS**
	1	2	3	4	1A	1B	1	2	3	
Hernández et al	Y	Y	Y	Y	Y	Y	N	Y	Y	8
COHORT STUDIES	**SELECTION**				**COMPARABILITY**		**OUTCOME**			**TOTAL OF STARS**
	1	2	3	4	1A	1B	1	2	3	
Abrishami et al	Y	Y	Y	Y	Y	Y	Y	Y	Y	9
Baktash et al	Y	Y	Y	Y	Y	N	Y	Y	Y	8
Barassi et al	Y	Y	Y	Y	Y	N	Y	Y	Y	8
Bennouar et al	Y	Y	Y	Y	Y	Y	Y	Y	Y	9
Cereda et al	Y	Y	Y	Y	Y	Y	Y	Y	Y	9
Jain et al	Y	Y	Y	Y	N	N	Y	Y	Y	7
Karahan & Katkat	Y	Y	Y	Y	Y	Y	Y	Y	Y	9
Radujkovic et al	Y	Y	Y	Y	Y	Y	Y	Y	Y	9
Smet et al	Y	Y	Y	Y	Y	Y	Y	Y	Y	9
Vassiliou et al	N	Y	Y	Y	Y	N	Y	Y	Y	7



Fig. 1. Flow chart of study selection



Fig. 2. Association of plasma vitamin D levels with mortality in COVID-19 patients by cut-off of 25(OH)D.



Fig. 3. Association between plasma vitamin D levels and mortality in patients with COVID-19, including studies that adjusted the analysis for age and at least one more confounder (age, obesity, hypertension, diabetes, kidney disease and Cardiovascular Disease) and studies without adjust for confounders.



Fig. 4 Funnel plot, using data from 11 studies associating plasma vitamin D levels and mortality. Two studies were included twice because they analysed two cut-offs of 25(OH)D.